A DNA fragment responsible for resistance to antimicrobial agents was cloned from chromosomal DNA of Enterococcus faecium FN-1, a clinically isolated strain. Escherichia coli KAM32, a drug-hypersusceptible mutant, was used as a host for gene cloning. Cells of E. coli KAM32 harboring a recombinant plasmid (pTFM8) carrying the DNA fragment became resistant to fluoroquinolones, macrolides, ethidium bromide, 4,6-diamidino-2-phenylindole (DAPI) and tetraphenylphosphonium chloride (TPPCl). Three complete open reading frames (ORFs) were found in the DNA insert of pTFM8, and the deduced amino acid sequences of one of the ORFs showed high similarity to Mdt(A) from Lactococcus lactis. Mdt(A) is a multidrug efflux pump belonging to a major facilitator superfamily. We designated the ORF efmA. E. coli KAM32 cells harboring the efmA showed energy-dependent efflux of DAPI and TPP ؉ . We also observed norfloxacin/H ؉ antiport due to EfmA. The mRNA expression of efmA was observed in E. faecium FN-1 grown without any exogenously added antimicrobial agents. Thus, we conclude that efmA is constitutively expressed under laboratory growth conditions and would contribute to intrinsic resistance against multiple antimicrobial agents in E. faecium FN-1.
Enterococci are normally found in the gastrointestinal tract of humans and other mammals. The Enterococci are of relatively low virulence, but sometimes cause urinary tract infections, bacteremia and endocarditis to postsurgical patients and in patients who possess pre-existing diseases. Consequently, Enterococci are one of the important nosocomial infectious microbes.
Enterococci are intrinsically resistant to many antimicrobial agents used in hospitals. 1, 2) Vancomycin is usually an effective antibiotic on Enterococci. However, Enterococci have eventually acquired resistance to vancomycin and other glycopeptides. Thus, vancomycin-resistant Enterococci (VRE) have emerged and developed a serious concern for clinical therapy all over the world. Additionally, most VRE show acquired high level resistance against various antibiotics such as aminoglycosides, b-lactams and so on. [3] [4] [5] [6] Only a few effective drugs are available for the treatment of VRE infection nowadays. Therefore therapy for VRE infection with antibiotics is becoming more and more difficult. 7) Of the bacteria belonging to the Enterococci, Enterococcus faecalis and Enterococcus faecium are common isolates from human infections. 8) Although most clinically isolated Enterococci are E. faecalis, most of the VRE are E. faecium. [9] [10] [11] [12] Therefore, it is important to get insight into systems and mechanisms of drug resistance in E. faecium.
Drug efflux is an important drug resistance mechanism in bacteria. It has been revealed that multidrug efflux pumps contribute to intrinsic and/or acquired resistance against various antimicrobials in bacteria. 13) However, only a few drug efflux pumps such as MsrC, Tet(K) and Tet(L) have been reported in E. faecium. MsrC 14) shows high similarity to MsrA/B, a drug efflux pump 15) reported in Staphylococcus epidermidis. MIC values for macrolides are lowered in msrC gene-disrupted E. faecium compared with the parent; therefore, this msrC determinant is involved in resistance to macrolides in this bacterium. 16) The genes tet(K) and tet(L) encode tetracycline efflux pumps. It has been reported that some E. faecium strains isolated from food possess these genes. 17) MsrC, Tet(K) and Tet(L) pumps are specific for macrolides or tetracycline. No multidrug efflux pump has been reported in E. faecium, so far. We believe that multidrug efflux pumps are important for multidrug resistance in the bacteria, too.
Thus, we aimed to clone genes for multidrug efflux pumps from E. faecium and to characterize the pumps. Here we report the gene cloning and properties of a multidrug efflux pump named EfmA from E. faecium.
MATERIALS AND METHODS
Bacteria and Growth E. faecium FN-1, 18) used as a donor of chromosomal DNA, was kindly provided by Dr. Y. Ike (Gunma University). This strain is a clinical isolate. The FN-1 showed resistance against multiple antimicrobials, such as erythromycin, 18) gentamicine, 18) norfloxacin (MIC, Ͼ128 mg/ml), vancomycin (MIC, Ͼ128 mg/ml), ethidium bromide (MIC, 64 mg/ml). Escherichia coli KAM32 (DacrB, DydhE, hsd Ϫ ) 19) was used as a host. Bacillus subtilis ISW1214 (hsrM1, leuA8, metB5; Tet s ) (TaKaRa Co.) was also used as a host. E. faecium cells were grown in Brain Heart Infusion broth (Becton, Dickinson & Co.), and E. coli and B. subtilis cells were grown in L medium 20) at 37°C. Cell growth was monitored by measuring optical density at 650 nm.
Gene Manipulation Chromosomal DNA was prepared from E. faecium cells by the method of Berns and Thomas. 21) The DNA was partially digested with Sau3AI, and the fragments from 4 to 10 kbp were collected after sucrose density gradient centrifugation. Plasmid pUC18 and pBR322 was digested with BamHI and dephosphorylated with shrimp alkaline phosphatase (Roche Diagnostics K.K.), and then ligated to the chromosomal DNA fragment by using a ligation kit Ver.2 (TaKaRa Co.). E. coli KAM32 cells transformed with the recombinant plasmids were spread on L agar plates containing 100 mg/ml of ampicillin and each antimicrobial agent. The concentrations of antimicrobial agents used for selection in the plate were as follows: 0.05 mg/ml of norfloxacin, 16 mg/ml of tetraphenylphosphonium chloride (TPPCl), 1 mg/ml of 4Ј,6-diamidino-2-phenylindole (DAPI), 8 mg/ml of rhodamine 6G, 12 mg/ml of ethidium bromide, 4 mg/ml of gentamicin, 8 mg/ml of acriflavine. The plates were incubated at 37°C for 24 h. We obtained eleven transformants harboring recombinant plasmids (seven plasmids with pUC18 as a vector and four plasmids with pBR322 as a vector) from plates containing norfloxacin, three transformants harboring recombinant plasmids (two plasmids with pUC18 as a vector and one plasmid with pBR322 as a vector) from plates containing TPPCl, two transformants harboring recombinant plasmids (with pBR322 as a vector) from plates containing DAPI, and three transformants harboring recombinant plasmids (with pUC18 as a vector) from plates containing rhodamine 6G. We also attempted to obtain recombinant plasmids from plates containing ethidium bromide, gentamicin or acriflavine, but no candidate was obtained. The recombinant plasmids were isolated from each transformant, retransformed into E. coli KAM32 cells and spread onto the same type of plates. We confirmed elevated drug resistance with the retransformants. The nucleotide sequence was determined by the dideoxy chain termination method 22) using a DNA sequencer (ABI PRISM 3100-Avant Genetic Analyzer, Applied Biosystems Co.). The sequence data have been deposited in the DDBJ, EMBL, and GenBank nucleotide sequence databases with the accession no. AB467372.
Drug Susceptibility Test The MICs of various antimicrobial agents (norfloxacin, ofloxacin, ciprofloxacin, erythromycin, oleandomycin, roxithromycin, clarythromycin, ethidium bromide, DAPI, and TPPCl) were determined in Mueller-Hinton broth (Difco, Sparks, U.S.A.) by the twofold dilution method. 23) We measured the MICs three times and obtained the same results.
DAPI Efflux Assay DAPI efflux assay was carried out as previously described.
24)

TPP
؉ Accumulation Assay A TPP ϩ electrode was used for measurement of TPP ϩ accumulation-efflux in cells. The TPP ϩ electrode was constructed as reported previously. 25) The E. coli cells harboring recombinant plasmids were grown in Tanaka medium supplemented with 1% tryptone, 20 mM potassium lactate and 10 mg/ml of chloramphenicol at 37°C until OD 650 of 0.5. The cells were harvested and washed 3 times with 0.1 M MOPS-KOH, pH 7.0. The cells were incubated at 37°C for 5 min with 20 mM potassium lactate. Cells (0.3 mg of protein/ml) were added to the assay medium containing 0.1 M MOPS-KOH, 20 mM potassium lactate, 2 mM TPPCl. Polymyxin B (the final concentration was 200 mM) was added to disrupt the membrane. The change in extracellular TPP ϩ concentration was monitored with a TPP ϩ electrode at room temperature.
Norfloxacin/H
؉ Antiport Assay Everted membrane vesicles were prepared as described previously. 26) Norfloxacin/H ϩ antiport activity was measured by the quinacrine fluorescence quenching method as described previously.
26)
RNA Preparation RNA was isolated from E. faecium cells grown in Brain Heart Infusion broth and harvested at OD 650 of 0.7 by using an RNeasy mini kit (QIAGEN) as suggested by the manufacturer's protocol with a slight modification in that we used lysozyme at a final concentration of 10 mg/ml instead of 3 mg/ml. Ten micrograms of RNA was treated with RQ1 RNase-free DNase (Promega) (1 U/mg of RNA) for 2 h, and purified by using RNeasy Mini Kit (Qiagen). When necessary, one of the following of antimicrobial agents was added to the growth medium; norfloxacin (32 mg/ml), erythromycin (512 mg/ml), gentamicin (2048 mg/ml), chloramphenicol (1 mg/ml), tetracycline (4 mg/ml), ethidium bromide (8 mg/ml), TPPCl (64 mg/ml) and benzalkonium chloride (0.5 mg/ml). These concentrations were 1/8 of their MICs.
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) RT-PCR was performed using the Qiagen OneStep RT-PCR Kit (Qiagen). One nanogram of DNase-treated RNA and 0.6 mM each one of the specific internal primers were used for one reaction mixture (final volume: 12.5 ml). Reverse transcription was performed at 50°C for 30 min, and thereafter the following reaction was repeated: 94°C for 30 s, 50°C for 30 s, 72°C for 1 min, 27 cycles for atpB and 32 cycles for efmA. Controls without reverse transcription reaction were performed to evaluate the possibility that the product was amplified from contaminated DNA. Primers used for efmA were 5Ј-TCCAAATGCCAACGATCCA-3Ј and 5Ј-TAGAGCTGGCGCAATGATGA-3Ј, for atpB were 5Ј-TAAGCTTAGGCTGGTTCTCATTGC-3Ј and 5Ј-ACGAA-GACAAATGCTTGGATGC-3Ј. Five microliters of each reaction mixture was subjected to agarose X (NIPPON GENE Co.) gel electrophoresis (3% w/v), and amplified products were visualized using ethidium bromide.
RESULTS
Functional Cloning of Gene for Drug Resistance
We obtained 19 recombinant plasmids in our attempts to clone gene(s) responsible for drug resistance. We investigated the digestion patterns of the recombinant plasmids by several restriction enzymes, and drug resistance patterns of the transformants harboring each recombinant plasmid. It was revealed that 16 of the 19 plasmids possessed a common DNA fragment derived from chromosomal DNA of E. faecium. Thus, we focused on the 16 recombinant plasmids. Among them, pTFM8 and pNFM2 were estimated to possess the shortest DNA inserts. We determined the partial DNA sequences of pTFM8 and pNFM2. The pTFM8 plasmid is a pUC18 derivative isolated from a transformant that grew on a TPPCl plate, and pNFM2 is a pBR322 derivative isolated from a transformant that grew on a norfloxacin plate.
From the sequencing results, it was confirmed that pTFM8 and pNFM2 possess the almost same DNA region of the chromosome, and both carried three intact open reading frames (ORFs) and parts of two ORFs, according to the genome sequence information of E. faecium DO strain (DOE Joint Genome Institute, http://www.jgi.doe.gov/). Of the three predicted complete ORFs, the gene designated as Efae-DRAFT_1990 seemed to encode a protein whose primary structure is similar to known bacterial multidrug efflux pumps as shown below. We sub-cloned EfaeDRAFT_1990 into the multicloning site of pSTV28 and the resulting plasmid was named pSFM82. The pSFM82 plasmid carries Efae-DRAFT_1990 as a sole complete ORF from E. faecium. We confirmed that E. coli KAM32 harboring pSFM82 showed increased resistances to several antimicrobial agents including norfloxacin (data not shown). We named the gene efmA (E. faecium multidrug resistance). We also constructed a plasmid deleting the efmA gene from pTFM8, and confirmed that the resulting plasmid did not confer elevated drug resistance to E. coli KAM32 (Data not shown).
We determined the nucleotide sequence of the insert in the pSFM82 plasmid, and EfmA was estimated to consist of 428 amino acid residues. Compared with the DNA sequence of EfaeDRAFT_1990 in the genome database from E. faecium DO, A at position 1227 was replaced with T in the efmA gene from E. faecium FN-1. Consequently, the single amino acid residue in EfmA was different between E. faecium DO and E. faecium FN-1 (lysine residue in the DO strain and asparagine residue in the FN-1 strain) .
A promoter-like sequence was present in the upstream of efmA. We constructed pSFM83 to investigate whether the promoter-like sequences function as a promoter in E. coli cells. The efmA gene in the pSFM83 plasmid is located in the opposite direction of the lac promoter in the vector. E. coli KAM32 cells introduced with the pSFM83 plasmid were able to grow on an L-plate containing 0.05 mg/ml of norfloxacin, although the control cells were unable to grow. Therefore we conclude that the deduced promoter is functional even in E. coli cells.
Homologs of EfmA We investigated the amino acid sequence homology and similarity between EfmA and reported sequences with BLAST (http://blast.ncbi.nlm.nih.gov/Blast. cgi). The EfmA sequence showed high similarity with Mdt(A) from Lactococcus lactis 27) (86% similarity), MefA from Streptococcus pyogenes 28) (76% similarity) and MefE from Streptococcus pneumoniae 29) (78% similarity). They are all drug efflux pumps belonging to the major facilitator superfamily (MFS). Thus, we conclude that EfmA is a multidrug efflux pump belonging to this family. The ortholog of EfmA was not found in the genome database of E. faecalis V583 (http://cmr.jcvi.org/tigr-scripts/CMR/GenomePage. cgi?database=gef). In most Enterococci, the genome project has not been completed. It seems possible that some of them possess the gene similar to efmA. Mdt(A) from L. lactis and MefE from S. pneumoniae are predicted to possess twelve transmembrane segments. Our result of hydropathy analysis using the Genetyx-Mac (GENETYX Co.) and SOSUI program (http://bp.nuap.nagoya-u.ac.jp/sosui/) also predicted that EfmA possesses 12 transmembrane domains.
Multidrug Resistance due to efmA We tested changes in the susceptibility of E. coli KAM32/pSFM82 cells to many antimicrobial agents ( Table 1) . Introduction of pSFM82 made E. coli KAM32 cells more resistant to fluoroquinolones, such as norfloxacin and ciprofloxacin, macrolides such as erythromycin and oleandomycin (Table 1) compared with control. Elevated MICs of ethidium bromide, DAPI and TPPCl were also observed with E. coli cells possessing efmA, but no increases in the MICs were observed for clarithromycin (Table 1) , kitasamycin and rokitamycin (data not shown). Thus, EfmA could confer resistance to multiple drugs to an E. coli host.
We previously constructed E. coli KAM42 30) which is a tolC-disrupted mutant from E. coli KAM32. TolC is an outer membrane channel protein which is involved in the extrusion of drugs and proteins. The drug resistant levels of E. coli KAM42 were slightly lower than that of E. coli KAM32. We introduced pSTV28 (control) or pSFM82 (carrying efmA) into cells of E. coli KAM42. Elevated MICs of norfloxacin and TPPCl were observed with E. coli KAM42/pSFM82 compared with E. coli KAM42/pSTV28 (Table 1) . We observed no increase, however, in the MICs of erythromycin and oleandomycin with E. coli KAM42/pSFM82 compared to E. coli KAM42/pSTV28 (Table 1) . Similar results were obtained with other tolC-disrupted E. coli strains (our laboratory collection) (data not shown). These results suggest that an outer membrane channel protein TolC is necessary for extrusion of these macrolides out of cells via EfmA in E. coli cells.
Drug Resistance Due to efmA in a Gram-Positive Bacterium Cells of B. subtilis ISW1214 were transformed with a plasmid pHFM2 carrying the efmA gene. B. subtilis ISW1214/pHFM2 showed elevated MICs of erythromycin and oleandomycin compared with the control (Table 1) . Whereas no increase in the MIC of norfloxacin was observed in B. subtilis ISW1214/pHFM2 compared with the control. The resistance level for norfloxacin is intrinsically high in B. subtilis cells. Therefore it may be difficult to observe an elevated MIC of norfloxacin with B. subtilis cells.
Efflux of DAPI and TPP
؉
We measured DAPI efflux activity in E. coli KAM32/pSFM82 cells (possessing efmA) and compared with that in E. coli KAM32/pSTV28 cells (control). We observed strong DAPI efflux from E. coli KAM32/pSFM82 cells loaded with DAPI after addition of lactate, a respiratory substrate, but not with E. coli KAM32/pSTV28 cells (Fig. 1 ). Thus, we were able to detect energy-dependent DAPI efflux due to the EfmA pump, and to prove that the EfmA is actually a drug efflux pump. We also measured a change in the extracellular level of TPP ϩ using TPP ϩ -specific electrode and estimated the efflux activity of TPP ϩ due to the EfmA pump. When E. coli KAM32/pSTV28 (control) cells were added to the assay mixture containing TPPCl, TPP ϩ was taken up by the cells, and the TPP ϩ concentration in the assay medium decreased and reached a certain plateau level (Fig. 2, chart a) . TPP ϩ came out from cells after addition of polymyxin B which disrupts the membrane permeability barrier. When E. coli KAM32/pSFM82 cells possessing the efmA gene were added to the assay mixture TPP ϩ was taken up by the cells. The TPP ϩ concentration in the assay medium was higher compared with that in the case of control cells (Fig. 2, chart b) . This means that the intracellular concentration of TPP ϩ in E. coli KAM32/pSFM82 cells was lower than that in E. coli KAM32/pSTV28 cells due to a stronger efflux of TPP ϩ in the former cells. The TPP ϩ concentration in the medium became the same after the addition of polymyxin B with both types of cells (Fig. 2) . 26) Therefore, we tested whether H ϩ /norfloxacin antiport was observed by using the fluorescence quenching method. Fluorescence dequenching of quinacrine elicited by addition of norfloxacin, which represents H ϩ /norfloxacin antiport, was observed with everted membrane vesicles prepared from E. coli KAM32/pSFM82 carrying efmA, but not with vesicles prepared from E. coli KAM32/pSTV28 (control) (Fig. 3) . Thus, we conclude that the EfmA is an H ϩ /substrate antiporter. This result is consistent with the general view that drug efflux pumps belonging to the MFS extrude drugs in exchange for H ϩ . 26, 31) Expression of efmA in E. faecium We investigated whether the efmA gene is constitutively expressed in E. faecium FN-1 cells grown under laboratory growth conditions. We detected a band representing expression of the efmA gene in E. faecium FN-1 cells (data not shown). Therefore we conclude that efmA is constitutively expressed in E. faecium FN-1 cells. Thus, EfmA would contribute to intrinsic resistance of E. faecium to several antimicrobial agents. It has been reported that rhodamine 6G and TPPCl, substrates of B. subtilis multidrug efflux pump Bmr, enhanced bmr expression at the level of transcription. 32) We previously reported that gene expression of mexCD in Pseudomonas aeruginosa was induced when cells were grown in the presence of several antimicrobial agents or disinfectants. 33) Therefore we tested whether expression of efmA in E. faecium cells is elevated when cells were grown in the presence of one of the following antimicrobial agents: norfloxacin, erythromycin, gentamicin, chloramphenicol, tetracycline, ethidium bromide, TPPCl or benzalkonium chloride. However, none of these antimicrobial agents gave significant changes in the expression of the efmA (data not shown).
DISCUSSION
We isolated 19 hybrid plasmids that conferred elevated drug resistances to an E. coli host in this study. Sixteen of Everted membrane vesicles of E. coli KAM32/pSTV28 (control) (a) and E. coli KAM32/pSFM82 (carrying efmA) (b) were used. The norfloxacin/H ϩ antiport activity due to EfmA was measured by the quinacrine fluorescence quenching method. At the time point indicated by the first arrow (Lactate), potassium lactate (final 5 mM) was added to initiate respiration. After the fluorescence quenching reached a steady-state level, norfloxacin (final 10 mM) was added to the assay mixture at the second arrow (NFLX). Finally at the time pointed indicated by the third arrow, Triton X-100 was added (final 0.0125%) to collapse the membrane barrier function.
these plasmids conferred multidrug resistance, and 3 remaining plasmids conferred resistance against a single antimicrobial agent. The 16 plasmids were found to carry the same DNA region derived from the chromosomal DNA of E. faecium. We identified a gene responsible for the observed multidrug resistance, and designated the gene efmA. So far, we have cloned many genes and operons encoding multidrug efflux pumps from chromosomes of several bacteria using the same strategy as the one used in this study. 24, [34] [35] [36] [37] [38] [39] Based on the available genome sequence information of E. faecium, we estimated that about 25 putative genes (operons) encoding multidrug efflux pumps exist in the chromosome of E. faecium. We do not know the reasons why we could clone only the efmA gene repeatedly, and why we were unable to clone other genes (operons) for multidrug resistance. One possible reason might be as follows. We used E. coli KAM32, a drug hyper-susceptible mutant, as a cloning host. E. coli would be suitable for gene cloning of Gram-negative bacteria. However, it has been reported that genes from Gram-positive bacteria were often unable to express efficiently in E. coli cells. 40) Many genes from E. faecium, a Gram-positive bacterium, might not be able to express in E. coli cells. Furthermore, many membrane proteins derived from E. faecium genes produced in E. coli cells might not be functional because of the difference in the membrane structures between a Gram-negative and a Gram-positive bacterium, or that such membrane proteins might be unstable in E. coli cells.
We sub-cloned the efmA gene together with the deduced promoter region into a vector plasmid. The efmA gene is located downstream of the lac promoter in the vector in pSFM82, and efmA is inserted in the opposite direction of the lac promoter in pSFM83. Both of the plasmids conferred elevated resistances against several antimicrobial agents in E. coli KAM32. However, E. coli KAM32/pSFM82 showed higher MICs of antimicrobial agents than E. coli KAM32/pSFM83. This means that the deduced promoter region present upstream of efmA would be functional even in E. coli cells. The fact that efmA was functionally cloned in E. coli cells also support this view. We found a DNA region which could form a stem-loop structure followed by a T-cluster in the downstream portion of the efmA gene, which could be a terminator of transcription. Thus, it seems that efmA forms a monocistronic operon. Although we checked the upstream and downstream regions of the efmA gene in the genome database (http://www.jgi.doe.gov/) for the presence of ORFs that encode regulator-like proteins, there were no such ORFs.
The deduced primary structure of EfmA was similar to that of MefA 28) in S. pyogenes and of MefE 29) in S. pneumoniae, both of which have been reported as macrolide efflux pumps. 28, 29) Both pumps recognize a 14-and a 15-, but not a 16-membered macrolide. This tendency for macrolides in MefA and MefE is similar to the substrate specificity in EfmA. Thus, EfmA might possess a common macrolide recognition region(s) with MefA and MefE. On the other hand, MefE does not recognize quinolones, TPPCl and ethidium bromide as substrates, 29) although these antimicrobial agents are substrates for the EfmA pump.
There was no difference in the MICs of norfloxacin and TPP ϩ between E. coli KAM32/pSFM82 possessing TolC and E. coli KAM42/pSFM82 (not possessing TolC) ( Table 1) .
This means that EfmA does not require the TolC for extrusion of norfloxacin and TPP ϩ . However, there was a reproducible difference in the MICs of erythromycin and oleandomycin between E. coli KAM32/pSFM82 and E. coli KAM42/pSFM82 (Table 1) . This suggests that either 1) TolC is necessary for extrusion through EfmA to the exterior of the outer membrane of macrolides that possess comparatively bulky or hydrophobic regions in their molecules or 2) another efflux pump(s) that requires TolC is also necessary for extrusion of macrolides. Lee and coworkers reported that the combination of a single-component efflux pump with a multi-component efflux pump conferred much higher antibiotic resistance than that by each one of the pumps. 41) Our results are consistent with their view.
Oyamada et al. reported that an efflux pump(s) in E. faecium might play a role in norfloxacin resistance in mutants although they did not identify the responsible gene(s).
42) The efmA gene might be the one they suggested to be involved in norfloxacin resistance.
Recently it has been reported that drug efflux pumps not only expel antibiotics and toxic compounds from cells but also play other physiological roles in the cells. For example, MdfA of E. coli, a multidrug efflux pump, also functions as a Na ; MacAB of E. coli, a macrolide efflux pump, extrudes enterotoxin from the periplasm to the medium 45) ; YerP of B. subtilis extrudes surfactin. 46) EfmA is expressed constitutively in cells of E. faecium FN-1. Therefore EfmA might also play physiological role(s) other than drug efflux.
